Researchers are studying the characteristics and prognosis of HER2-low breast cancer, comparing it to HER2-zero and HER2-positive disease. The studies are examining various aspects, including tumor-infiltrating lymphocytes, androgen receptor expression, and clinicopathological features. Findings from these studies may help shed light on the clinical and molecular characteristics of HER2-low breast cancer and its potential treatment options.